PALVELLA THERAPEUTICS, INC. current report, 04 June 2017

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (noting a discrepancy in the request metadata which listed "Palvella Therapeutics, Inc."). The report covers events occurring on June 4, 2017, specifically the presentation of clinical study results at the 54th European Renal Association & European Dialysis and Transplant Association (ERA-EDTA) Congress in Madrid, Spain.

Key Financial Metrics

This filing is a Regulation FD disclosure regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

The material event reported is the presentation of Phase 1b study results for the company's anemia program, designated PRS-080#022-DP. No financial material changes versus prior periods are disclosed in this document.

Guidance, Outlook, and Risks

  • Management Commentary: The company presented data on its anemia program at a major medical congress. The full details are contained in the attached poster (Exhibit 99.1) and press release (Exhibit 99.2).
  • Legal Status of Information: The information under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
  • Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K; investors are directed to the exhibits for clinical data.

Investor Verification Checklist

  • Verify the clinical data and conclusions presented in the Phase 1b study poster (Exhibit 99.1).
  • Review the full press release (Exhibit 99.2) for management's interpretation of the PRS-080#022-DP results.
  • Confirm the company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
  • Note the discrepancy between the request metadata ("Palvella Therapeutics") and the actual registrant ("Pieris Pharmaceuticals").